

alterations in expression of the TGF $\beta$  receptors I and II (T $\beta$ RI and T $\beta$ RII) are also observed during pancreatic cancer progression. These observations are consistent with an integral role of the TGF $\beta$  pathway components in pancreas biology and disease progression. However, the molecular details and the target cell population of TGF $\beta$  signals during pancreas development and disease are not known.

SMAD proteins are downstream mediators of signals from TGF $\beta$  1,2,3 and activin, and SMAD proteins have been implicated as important factors in cellular proliferation, differentiation and migration. This invention identifies another important regulatory role for the TGF $\beta$ -signaling pathway in insulin production. The inventors have shown that low levels of TGF $\beta$  can suppress insulin production through the actions of the SMAD signaling proteins. Small molecule regulators of SMAD-dependent signaling may lead to better insulin production and allow better glucose regulation. Thus, controlled administration of TGF $\beta$  signaling regulators may be useful in the treatment of diabetes, hyperglycemia and related complications.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

#### **Anti-Marinobufagenin Antibodies and Methods for Their Use**

Alexei Bagrov *et al.* (NIA).  
U.S. Provisional Application No. 60/694,733 filed 27 Jun 2005 (HHS Reference No. E-092-2004/0-US-01).  
*Licensing Contact:* Fatima Sayyid; 301-435-4521; [sayyidf@mail.nih.gov](mailto:sayyidf@mail.nih.gov).

Pre-eclampsia is associated with increased blood levels of marinobufagenin (MBG), a steroid that increases blood pressure by inhibiting a membrane enzyme, Na/K ATPase, in the vascular wall. Pre-eclampsia complicates up to 10% of pregnancies in the U.S. and is a significant factor in causing maternal and fetal mortality and morbidity worldwide.

The present invention relates to compositions and methods for detecting the presence of MBG in a biological sample. It also relates to methods for the use of monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of hypertension.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Dated: August 5, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-16138 Filed 8-12-05; 8:45 am]

**BILLING CODE 4140-01-P**

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **Substance Abuse and Mental Health Services Administration**

##### **Center for Substance Abuse Treatment; Notice of Meeting**

Pursuant to Public Law 92-463, notice is hereby given of a Teleconference Meeting of the Center for Substance Abuse Treatment (CSAT) National Advisory Council to be held August 15, 2005.

The meeting will include the review, discussion and evaluation of grant applications reviewed by Initial Review Groups. Therefore, the meeting will be closed to the public as determined by the SAMHSA Administrator, in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App. 2, 10(d).

Substantive program information and a roster of Council members may be obtained by accessing the SAMHSA Advisory Council Web site (<http://www.samhsa.gov>) as soon as possible after the meeting, or by communicating with the contact whose name and telephone number are listed below.

*Committee Name:* Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment National Advisory Council.

*Meeting Date:* August 15, 2005.

*Place:* 1 Choke Cherry Road, 5th Floor Conference Room, Rockville, MD 20857.

*Type:* Closed: August 15, 2005-11 a.m.-12 p.m.

*Contact:* Cynthia Graham, M.S., NAC Executive Secretary, SAMHSA/CSAT National Advisory Council, 1 Choke Cherry Road, Room 5-1036, Rockville, MD 20857. Telephone: (240) 276-1692. FAX: (240) 276-1690. E-mail:

[cynthia.graham@samhsa.hhs.gov](mailto:cynthia.graham@samhsa.hhs.gov).

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the Department and the review and funding cycle.

Dated: August 10, 2005.

**Toian Vaughn,**

*Committee Management Officer, Substance Abuse and Mental Health, Services Administration.*

[FR Doc. 05-16164 Filed 8-12-05; 8:45 am]

**BILLING CODE 4162-20-P**

#### **DEPARTMENT OF THE INTERIOR**

##### **Fish and Wildlife Service**

##### **Information Collection Renewal To Be Sent to the Office of Management and Budget (OMB) for Approval Under the Paperwork Reduction Act; OMB Control Number 1018-0119; Policy for Evaluating Conservation Efforts When Making Listing Decisions**

**AGENCY:** Fish and Wildlife Service, Interior.

**ACTION:** Notice; request for comments.

**SUMMARY:** We (Fish and Wildlife Service, Service) plan to send OMB a request to renew approval for information collections associated with our Policy for Evaluation of Conservation Efforts When Making Listing Decisions (PECE). We use the information that we collect as part of the basis for identifying conservation efforts that can contribute to a decision to not list a species under the Endangered Species Act (ESA) or to list a species as threatened rather than endangered.

**DATES:** You must submit comments on or before October 14, 2005.

**ADDRESSES:** Send your comments on this information collection to Hope Grey, Information Collection Clearance Officer, Fish and Wildlife Service, MS 222-ARLSQ, 4401 North Fairfax Drive Arlington, Virginia 22203 (mail); [hope\\_grey@fws.gov](mailto:hope_grey@fws.gov) (e-mail); or (703) 358-2269 (fax).

**FOR FURTHER INFORMATION CONTACT:** To request a copy of the information collection requirements or explanatory material, contact Hope Grey, Information Collection Clearance Officer, at the above addresses or by telephone at (703) 358-2482. For information related to the Policy for Evaluation of Conservation Efforts When Making Listing Decisions, please visit our Web site at <http://www.fws.gov/endangered/listing/pece-final.pdf>.

**SUPPLEMENTARY INFORMATION:** The OMB regulations at 5 CFR 1320, which implement provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), require that interested members of the public and affected agencies have an opportunity to comment on information collection and recordkeeping activities (see 5 CFR 1320.8(d)). We will ask OMB to renew approval of the collection of information for certain types of conservation agreements, conservation plans, and similar documents in relation to PECE (68 FR 15100, March 28, 2003). The current OMB control number for this